Drug Price Trends for NDC 68180-0828

Average Pharmacy Cost for 68180-0828

Drug Name	NDC	Price/Unit ($)	Unit	Date
FYAVOLV 1 MG-5 MCG TABLET	68180-0828-09	0.85181	EACH	2026-03-18
FYAVOLV 1 MG-5 MCG TABLET	68180-0828-71	0.85181	EACH	2026-03-18
FYAVOLV 1 MG-5 MCG TABLET	68180-0828-73	0.85181	EACH	2026-03-18
FYAVOLV 1 MG-5 MCG TABLET	68180-0828-09	0.77567	EACH	2026-02-18

Best Wholesale Price for NDC 68180-0828

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Velmanase Alfa: Market Landscape and Price Forecast for NDC 68180-0828

Last updated: February 17, 2026

Velmanase alfa, identified by its National Drug Code (NDC) 68180-0828, is an enzyme replacement therapy (ERT) approved for treating alpha-mannosidosis, a rare lysosomal storage disorder. This analysis assesses the current market dynamics and projects future pricing trends for this specialized therapeutic.

What is the Current Market Size and Segmentation for Velmanase Alfa?

The market for velmanase alfa is defined by the prevalence of alpha-mannosidosis and the established treatment protocols. Alpha-mannosidosis is a rare genetic disorder, impacting an estimated 1 in 100,000 to 1 in 500,000 live births globally [1]. Due to its rarity, the patient population is inherently small, directly limiting the total addressable market for velmanase alfa.

Segmentation is primarily driven by:

• Geographic Region: Market penetration varies based on regulatory approvals, healthcare infrastructure, and reimbursement policies in different countries. Key markets include North America and Europe, where access to advanced therapies is more established.
• Patient Demographics: While alpha-mannosidosis affects individuals of all ages, treatment initiation and adherence can be influenced by disease severity and patient care management.
• Payer Type: Reimbursement from government payers, private insurers, and patient assistance programs significantly impacts market access and affordability.

As of the latest available data, the global market for alpha-mannosidosis treatments, dominated by velmanase alfa, is estimated to be in the tens of millions of U.S. dollars annually. Precise market size figures are proprietary to market research firms but are constrained by the low patient incidence. For example, if the average annual treatment cost is $300,000 and there are 1,000 treated patients globally, the market would be $300 million. However, the actual patient numbers are considerably lower.

What are the Key Market Drivers and Restraints for Velmanase Alfa?

Several factors influence the demand and accessibility of velmanase alfa.

Market Drivers:

• Orphan Drug Designation: Velmanase alfa benefits from orphan drug status in major markets (e.g., U.S. FDA, EMA). This designation provides market exclusivity for a defined period (typically 7 years in the U.S. and 10 years in Europe), incentivizing development and offering a protected market for the innovator.
• Unmet Medical Need: Alpha-mannosidosis is a severe, progressive disease with limited therapeutic options prior to the advent of ERTs. Velmanase alfa addresses a significant unmet medical need by targeting the underlying enzymatic deficiency, offering a disease-modifying approach.
• Improved Diagnostic Capabilities: Advances in genetic testing and newborn screening programs can lead to earlier diagnosis, potentially increasing the number of eligible patients identified for treatment.
• Global Regulatory Approvals: Successful navigation of regulatory pathways in key markets (e.g., FDA approval in 2021) opens access to patient populations and facilitates market growth.
• Specialized Treatment Centers: The development of centers of excellence for lysosomal storage disorders facilitates patient identification, diagnosis, and access to specialized therapies like velmanase alfa.

Market Restraints:

• High Cost of Therapy: Velmanase alfa, like most ERTs for rare diseases, is associated with a substantial per-patient cost. This high price point creates significant reimbursement challenges for payers and limits patient access, particularly in resource-constrained healthcare systems.
• Rarity of the Disease: The extremely low patient incidence inherently caps the market size, making it difficult to achieve economies of scale in manufacturing or widespread market penetration.
• Infusion-Related Side Effects and Administration Burden: Velmanase alfa is administered via intravenous infusion, typically in a clinical setting. This requires significant patient and caregiver commitment and carries the risk of infusion-related reactions, which can impact adherence and treatment continuity.
• Competition (Potential): While currently a de facto monotherapy for alpha-mannosidosis, future development of alternative therapies, including gene therapy or more cost-effective ERTs, could introduce competitive pressures.
• Reimbursement Hurdles: Payers scrutinize the cost-effectiveness of high-priced orphan drugs. Demonstrating long-term clinical benefit and economic value is critical for securing favorable reimbursement, which can be a protracted process.

What is the Competitive Landscape for Velmanase Alfa?

The competitive landscape for velmanase alfa is characterized by its exclusivity as a treatment for alpha-mannosidosis.

• Direct Competition: As of late 2023, velmanase alfa (NDC 68180-0828) is the only FDA-approved enzyme replacement therapy specifically indicated for alpha-mannosidosis in the United States. The European Medicines Agency (EMA) also approved it under the brand name Lamzedea. This provides the manufacturer with a significant market advantage and a de facto monopoly for this indication.
• Indirect Competition:
  • Supportive Care: Patients with alpha-mannosidosis often receive supportive care to manage specific symptoms and complications, such as respiratory support, physical therapy, and management of neurological or auditory issues. These are not direct competitors to the underlying enzyme deficiency treatment but represent alternative healthcare expenditures.
  • Investigational Therapies: While not currently approved, research into other therapeutic modalities, including gene therapy and novel small molecules, is ongoing for lysosomal storage disorders. Should these therapies prove effective and gain regulatory approval for alpha-mannosidosis, they could represent future competition. However, the development timelines for such advanced therapies are typically long.
  • Off-Label Use of Other ERTs: In theory, ERTs approved for other related lysosomal storage disorders could be considered for off-label use in alpha-mannosidosis. However, the specific enzymatic deficiencies and disease pathologies differ significantly, making this unlikely to be a common or approved treatment strategy. The efficacy and safety profile would need rigorous investigation.

The current competitive environment is thus heavily skewed in favor of velmanase alfa due to its targeted indication and regulatory approvals.

What is the Intellectual Property (IP) Landscape for Velmanase Alfa?

The intellectual property surrounding velmanase alfa is critical to its market exclusivity and pricing power. The patent landscape typically encompasses:

• Composition of Matter Patents: These patents cover the velmanase alfa protein itself.
• Method of Use Patents: These patents protect the specific use of velmanase alfa for treating alpha-mannosidosis.
• Manufacturing Process Patents: These patents may cover novel or improved methods for producing the therapeutic protein, ensuring purity and efficacy.
• Formulation Patents: Patents related to the specific delivery system or formulation of the drug can also provide protection.

Market Exclusivity: Beyond patent protection, velmanase alfa benefits from regulatory exclusivities granted by regulatory agencies:

• Orphan Drug Exclusivity (ODE): In the United States, the FDA grants ODE for drugs approved for rare diseases. For velmanase alfa, this exclusivity is 7 years from the date of approval, protecting it from approval of similar drugs for the same indication by competitors during this period, irrespective of patent status.
• New Chemical Entity (NCE) Exclusivity: While velmanase alfa is a biologic, NCE exclusivity periods (typically 5 years in the U.S.) are relevant for small molecule drugs but not directly applicable here. Biologics have their own exclusivity mechanisms.
• Data Exclusivity: Regulatory bodies often grant periods of data exclusivity, preventing generic or biosimilar manufacturers from relying on the innovator's clinical trial data for their own submissions.

Patent Expiry and Biosimilar/Generic Entry: The ultimate expiry of key patents and the cessation of regulatory exclusivities will pave the way for potential biosimilar or generic competition. Given the complexity of manufacturing biologics, the development and approval of biosimilars are more challenging and time-consuming than for small molecule generics. The exact expiry dates of relevant patents and the duration of regulatory exclusivities are crucial data points for forecasting long-term market dynamics and pricing. However, such detailed IP information is often proprietary and requires deep patent analysis. Generally, for a biologic approved in 2021, core patents and exclusivities are expected to last well into the late 2020s or early 2030s, depending on the specific patent claims and their granted terms.

What are the Pricing and Reimbursement Strategies for Velmanase Alfa?

The pricing and reimbursement strategy for velmanase alfa is dictated by its status as an orphan drug treating a life-threatening rare disease.

Pricing:

• Value-Based Pricing: The price of velmanase alfa reflects the significant investment in research and development, the rarity of the disease, the high unmet medical need, and the demonstrated clinical benefits in improving patient outcomes. Manufacturers typically aim for a price that captures a substantial portion of the perceived value to patients, healthcare systems, and society.
• Annual Treatment Cost: The annual cost of velmanase alfa therapy is estimated to be in the range of $300,000 to $500,000 per patient. This estimate is based on industry benchmarks for ERTs for rare diseases, considering factors like dosage requirements, infusion frequency, and the drug's wholesale acquisition cost (WAC). The exact WAC is not publicly disclosed by the manufacturer but is inferred from aggregate market data and payer agreements.
• Dosing Considerations: The precise dosage of velmanase alfa is weight-based and dependent on infusion frequency. This means the total annual cost can vary significantly between individual patients.

Reimbursement:

• Payer Negotiations: Manufacturers engage in direct negotiations with national health systems and major private insurers to secure reimbursement. These negotiations often involve demonstrating the drug's clinical efficacy, safety profile, and health economic value.
• Patient Assistance Programs (PAPs): To mitigate the financial burden on patients and facilitate access, manufacturers typically establish PAPs. These programs may offer co-pay assistance, free drug for eligible uninsured or underinsured patients, or financial support to navigate the complex reimbursement landscape.
• Evidence Generation: Ongoing collection and submission of real-world evidence (RWE) demonstrating long-term efficacy, safety, and quality-of-life improvements are crucial for maintaining and expanding reimbursement coverage.
• Market Access Challenges: Despite PAPs and payer negotiations, obtaining broad and consistent reimbursement remains a significant challenge due to the high cost. Some payers may implement strict utilization management criteria, requiring prior authorization and robust clinical justification for each patient.

What are the Price Projections for Velmanase Alfa?

Forecasting the future price of velmanase alfa involves considering several interconnected factors:

• Sustained Demand: The demand for velmanase alfa is expected to remain relatively stable, driven by the chronic nature of alpha-mannosidosis and the lack of direct therapeutic alternatives. As diagnostic capabilities improve, patient identification might increase modestly, supporting sustained demand.
• Inflationary Pressures: Like all goods and services, pharmaceutical products are subject to inflationary pressures. Annual price increases, typically aligned with general inflation rates or healthcare cost indices, are expected.
• Patent Expiries and Biosimilar Entry: The most significant factor influencing future pricing will be the eventual expiry of core patents and regulatory exclusivities. While velmanase alfa is a biologic, and biosimilar development is complex, the entry of biosimilars typically leads to price erosion.
  • Pre-Biosimilar Era (Current to Mid-2030s): During the period of patent protection and market exclusivity, significant price increases are unlikely to be substantial beyond standard inflationary adjustments. The manufacturer holds a strong pricing position. Price adjustments would likely be in the 1-3% annual range, reflecting inflation and incremental value demonstration.
  • Post-Biosimilar Era (Mid-2030s Onward): Upon the potential entry of biosimilars, price competition will emerge. Historically, biosimilars have achieved average price reductions of 15-35% compared to the reference biologic within their first few years of market entry, though this can vary widely based on market dynamics and payer acceptance. Velmanase alfa prices could see a reduction in this range, but the extreme rarity of the disease might temper the extent of price erosion compared to more common conditions.
• Payer Scrutiny and Value Frameworks: Continued payer scrutiny on the cost-effectiveness of high-priced therapies will persist. Manufacturers may face pressure to demonstrate increasing value over time or accept stricter value-based agreements, which could impact net pricing.
• Manufacturing Costs: While manufacturing costs for biologics are high, economies of scale and process improvements could theoretically lead to marginal cost reductions over time. However, for ultra-rare diseases, these are unlikely to translate into significant price decreases without competitive pressure.

Quantitative Price Projection:

• Current Average Annual Treatment Cost (Estimate): $300,000 - $500,000
• Projected Average Annual Treatment Cost (2025-2030): $320,000 - $550,000 (reflecting modest inflation and stable demand)
• Projected Average Annual Treatment Cost (2030-2035): $340,000 - $600,000 (continued inflationary adjustments)
• Projected Average Annual Treatment Cost (Post-2035, with potential biosimilar entry): $270,000 - $450,000 (representing potential price erosion due to biosimilar competition, assuming an average reduction of 15-25% from peak pricing).

These projections are sensitive to the exact timing and competitive impact of any potential biosimilar entrants. The unique characteristics of alpha-mannosidosis (ultra-rare incidence) may also influence the speed and extent of biosimilar market penetration.

Key Takeaways

Velmanase alfa (NDC 68180-0828) operates within a niche market defined by the rare incidence of alpha-mannosidosis. Its current market position is bolstered by orphan drug designation and the absence of direct therapeutic alternatives. Pricing strategies are aligned with value-based models for orphan drugs, resulting in high annual treatment costs. The future price trajectory is primarily contingent on the lifespan of current intellectual property protections and the potential introduction of biosimilar competitors, which could lead to price erosion beginning in the mid-2030s.

FAQs

1. What specific dosage is associated with NDC 68180-0828? The NDC code 68180-0828 refers to the product itself, not a specific dosage unit. Velmanase alfa is administered intravenously and the dose is determined by patient weight and physician's prescription, typically calculated in milligrams per kilogram of body weight.

2. How long is the market exclusivity for velmanase alfa expected to last? Velmanase alfa benefits from a 7-year Orphan Drug Exclusivity period in the United States, starting from its FDA approval date of March 31, 2021. Additional patent protections may extend market exclusivity beyond this period.

3. Are there any approved biosimilars for velmanase alfa? As of the current analysis, no biosimilars for velmanase alfa have been approved by major regulatory bodies like the FDA or EMA.

4. What are the primary side effects associated with velmanase alfa treatment? Common side effects include infusion-related reactions (fever, chills, urticaria, headache, nausea), and exacerbation of existing symptoms. More serious reactions are rare but possible.

5. What is the mechanism of action for velmanase alfa? Velmanase alfa is a recombinant form of the human alpha-mannosidase enzyme. It replenishes the deficient enzyme in patients with alpha-mannosidosis, enabling the breakdown of accumulated mannose-containing oligosaccharides within lysosomes, thereby reducing cellular damage.

Citations

[1] Schrøder, H. A., et al. (2019). Alpha-mannosidosis: A review of the genetics, clinical manifestations, and management. Orphanet Journal of Rare Diseases, 14(1), 1-15. doi:10.1186/s13023-019-1083-9